Hypoglycemia in patients with type 2 diabetes newly initiated on basal insulin in the US in a community setting: impact on treatment discontinuation and hospitalization

References

• Inzucchi SE, Bergenstal RM, Buse JB, et al. Management of hyperglycaemia in type 2 diabetes: a patient-centered approach. Position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care 2012;35:1364-7
   PubMed Web of Science ®Google Scholar
• Cobble ME, Peters AL. Clinical practice in type 2 diabetes: after metformin and lifestyle, then what? J Fam Pract 2009;58(11 Suppl Clinical):S7-S14
   Google Scholar
• Shomali M. Add-on therapies to metformin for type 2 diabetes. Expert Opin Pharmacother 2011;12:47-62
   PubMed Web of Science ®Google Scholar
• Inzucchi SE, Bergenstal RM, Buse JB, et al. Management of hyperglycemia in type 2 diabetes, 2015: a patient-centered approach: update to a position statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 2015;38:140-9
   PubMed Web of Science ®Google Scholar
• Lau AN, Tang T, Halapy H, et al. Initiating insulin in patients with type 2 diabetes. CMAJ 2012;184:767-76
   PubMed Web of Science ®Google Scholar
• Davis KL, Tangirala M, Meyers JL, Wei W. Real-world comparative outcomes of US type 2 diabetes patients initiating analog basal insulin therapy. Curr Med Res Opin 2013;29:1083-91
   PubMed Web of Science ®Google Scholar
• Xie L, Wei W, Pan C, Baser O. Real-world rates, predictors, and associated costs of hypoglycemia among patients with type 2 diabetes mellitus treated with insulin glargine: results of a pooled analysis of six retrospective observational studies. J Med Econ 2013;16:1137-45
   PubMedGoogle Scholar
• Ward A, Alvarez P, Vo L, Martin S. Direct medical costs of complications of diabetes in the United States: estimates for event-year and annual state costs (USD 2012). J Med Econ 2014;17:176-83
   PubMedGoogle Scholar
• Quilliam BJ, Simeone JC, Ozbay AB, Kogut SJ. The incidence and costs of hypoglycemia in type 2 diabetes. Am J Manag Care 2011;17:673-80
   PubMed Web of Science ®Google Scholar
• Curkendall SM, Natoli JL, Alexander CM, et al. Economic and clinical impact of inpatient diabetic hypoglycemia. Endocr Pract 2009;15:302-12
   PubMed Web of Science ®Google Scholar
• Bron M, Marynchenko M, Yang H, et al. Hypoglycemia, treatment discontinuation, and costs in patients with type 2 diabetes mellitus on oral antidiabetic drugs. Postgrad Med 2012;124:124-32
   PubMed Web of Science ®Google Scholar
• Lopez JM, Annunziata K, Bailey RA, et al. Impact of hypoglycemia on patients with type 2 diabetes mellitus and their quality of life, work productivity, and medication adherence. Patient Prefer Adherence 2014;8:683-92
   PubMed Web of Science ®Google Scholar
• Walz L, Pettersson B, Rosenqvist U, et al. Impact of symptomatic hypoglycemia on medication adherence, patient satisfaction with treatment, and glycemic control in patients with type 2 diabetes. Patient Prefer Adherence 2014;8:593-601
   PubMed Web of Science ®Google Scholar
• Ho PM, Rumsfeld JS, Masoudi FA, et al. Effect of medication nonadherence on hospitalization and mortality among patients with diabetes mellitus. Arch Intern Med 2006;166:1836-41
   PubMed Web of Science ®Google Scholar
• Rys P, Wojciechowski P, Rogoz-Sitek A, et al. Systematic review and meta-analysis of randomized clinical trials comparing efficacy and safety outcomes of insulin glargine with NPH insulin, premixed insulin preparations or with insulin detemir in type 2 diabetes mellitus. Acta Diabetol 2015;52:649-62
   PubMed Web of Science ®Google Scholar
• Levin P, Wei W, Miao R, et al. Therapeutically interchangeable? A study of real-world outcomes associated with switching basal insulin analogues among US patients with type 2 diabetes mellitus using electronic medical records data. Diabetes Obes Metab 2015;17:245-53
   PubMed Web of Science ®Google Scholar
• Hsu PF, Sung SH, Cheng HM, et al. Association of clinical symptomatic hypoglycemia with cardiovascular events and total mortality in type 2 diabetes: a nationwide population-based study. Diabetes Care 2013;36:894-900
   PubMed Web of Science ®Google Scholar
• Cryer PE. The barrier of hypoglycemia in diabetes. Diabetes 2008;57:3169-76
   PubMed Web of Science ®Google Scholar
• Amiel SA, Dixon T, Mann R, Jameson K. Hypoglycaemia in type 2 diabetes. Diabet Med 2008;25:245-54
   PubMed Web of Science ®Google Scholar
• CDC diabetes public health resource data & trends. Centers for Disease Control and Prevention. Available at: http://www.cdc.gov/diabetes/index.htm [Last accessed 10 October 2015]
   Google Scholar
• Polonsky WH, Fisher L, Guzman S, et al. Psychological insulin resistance in patients with type 2 diabetes: the scope of the problem. Diabetes Care 2005;28:2543-5
   PubMed Web of Science ®Google Scholar
• Peyrot M, Barnett AH, Meneghini LF, Schumm-Draeger PM. Factors associated with injection omission/nonadherence in the Global Attitudes of Patients and Physicians in Insulin Therapy study. Diabetes Obes Metab 2012;14:1081-7
   PubMed Web of Science ®Google Scholar
• Peyrot M, Barnett AH, Meneghini LF, Schumm-Draeger PM. Insulin adherence behaviours and barriers in the multinational Global Attitudes of Patients and Physicians in Insulin Therapy study. Diabet Med 2012;29:682-9
   PubMed Web of Science ®Google Scholar
• Krall J, Gabbay R, Zickmund S, et al. Current perspectives on psychological insulin resistance: primary care provider and patient views. Diabetes Technol Ther 2015;17:268-74
   PubMed Web of Science ®Google Scholar
• Edelman S, Pettus J. Challenges associated with insulin therapy in type 2 diabetes mellitus. Am J Med 2014;127(10 Suppl):S11-S16
   PubMed Web of Science ®Google Scholar
• Ayyagari R, Wei W, Cheng D, et al. Effect of adherence and insulin delivery system on clinical and economic outcomes among patients with type 2 diabetes initiating insulin treatment. Value Health 2015;18:198-205
   PubMed Web of Science ®Google Scholar
• DiBonaventura M, Wintfeld N, Huang J, Goren A. The association between nonadherence and glycated hemoglobin among type 2 diabetes patients using basal insulin analogs. Patient Prefer Adherence 2014;8:873-82
   PubMed Web of Science ®Google Scholar
• Campbell RK. Recommendations for improving adherence to type 2 diabetes mellitus therapy – focus on optimizing insulin-based therapy. Am J Manag Care 2012;18(3 Suppl):S55-S61
   PubMedGoogle Scholar